Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer

Patients with platinum-sensitive relapsed ovarian cancer who had undergone complete resection were assigned to undergo surgery and then receive chemotherapy or to receive chemotherapy alone. The median overall survival was 54 months with surgery and chemotherapy, and 46 months with chemotherapy alon...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2021-12, Vol.385 (23), p.2123-2131
Hauptverfasser:	Harter, Philipp, Sehouli, Jalid, Vergote, Ignace, Ferron, Gwenael, Reuss, Alexander, Meier, Werner, Greggi, Stefano, Mosgard, Berit J, Selle, Frederic, Guyon, Frédéric, Pomel, Christophe, Lécuru, Fabrice, Zang, Rongyu, Avall-Lundqvist, Elisabeth, Kim, Jae-Weon, Ponce, Jordi, Raspagliesi, Francesco, Kristensen, Gunnar, Classe, Jean-Marc, Hillemanns, Peter, Jensen, Pernille, Hasenburg, Annette, Ghaem-Maghami, Sadaf, Mirza, Mansoor R, Lund, Bente, Reinthaller, Alexander, Santaballa, Ana, Olaitan, Adeola, Hilpert, Felix, du Bois, Andreas
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antineoplastic Agents - therapeutic use Ascites Cancer therapies Chemotherapy Combined Modality Therapy Cytoreduction Surgical Procedures Female Gynecologic Oncology Gynecology Hematology Humans Medical prognosis Middle Aged Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - mortality Neoplasm Recurrence, Local - surgery Obstetrics Oncology Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - mortality Ovarian Neoplasms - surgery Patients Platinum Proportional Hazards Models Quality of Life Statistical analysis Surgery Surgery General Survival Survival Analysis Treatments in Oncology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Patients with platinum-sensitive relapsed ovarian cancer who had undergone complete resection were assigned to undergo surgery and then receive chemotherapy or to receive chemotherapy alone. The median overall survival was 54 months with surgery and chemotherapy, and 46 months with chemotherapy alone.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2103294